Pharmaceutical Biotech (02269) rose more than 5%. As of press release, it was up 5.01% to HK$1,424, with a turnover of HK$472 million.
The Zhitong Finance App learned that Yao Ming Biotech (02269) rose by more than 5%. As of press release, it had risen 5.01% to HK$14.24, with a turnover of HK$472 million.
According to the news, Yao Ming Biotech announced its 2023 annual results, with revenue of 17.034 billion yuan (RMB, same below), an increase of 11.6% over the previous year; the company's owners should account for 3.4 billion yuan in net profit. Notably, the company's business rebounded significantly in the second half of 2023. The number of comprehensive projects increased from 588 in the same period last year to 698 as of December 31, 2023, including 132 new integrated projects and a record for the number of new non-COVID-19 projects added each year. As of December 31, 2023, the number of commercial production projects increased from 17 last year to 24, while 9 “winning molecules” post-clinical and commercial production projects were added, reaching a record high.